A Phase 2 interventional study of Ixabepilone and Cetuximab in Metastatic Pancreatic Cancer, sponsored by R-Pharm. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.
Sponsored by R-Pharm · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing cetuximab in Pancreatic Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Cetuximab · Pancreatic Neoplasms.
Among the 21 studies testing cetuximab in Pancreatic Neoplasms, this one is the 10th largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 2, and was the 10th registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →1 of the 21 studies testing cetuximab in Pancreatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17
First in 1999; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 44 across the 21 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
R-Pharm has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing cetuximab in Pancreatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants were administered ixabepilone at a starting dose of 32 mg/m\^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m\^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m\^2 IV over 1 hour).
Drug: Ixabepilone · Drug: Cetuximab
Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
Also known as: IXEMPRA®, Erbitux®, BMS-247550, BMS-564717
Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
Percentage of Participants Surviving at 6 Months
The percentage of participants surviving at 6 months was defined as the number of treated participants who had not died prior to 6 months from the date of their first dose divided by the total number of treated participants.
Time frame: From time of first dose of study drug through 6 months
Best Overall Tumor Response
Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD; Stable Disease (SD)= neither PR nor progressive disease (PD) criteria were met; PD = at least 20% increase in the sum of the LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.
Time frame: From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression)
Percentage of Participants With Objective Tumor Response
Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions.
Time frame: From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression
Median Progression Free Survival Time
Progression-Free Survival (PFS) time was defined as the time, in months, from the first dosing date until the date of disease progression or death from any cause.
Time frame: From time of first dose of study until 16.49 months (longest period for participant between first dose and documented disease progression
Median Overall Survival Time
Overall survival time was defined as the time in months from the first dosing date to the date of death.
Time frame: From the first dosing date until death (last reported death was 21 months after first dose).
Median Duration of Response
Duration of response was defined as the number of months from when measurement criteria were first met for CR or PR (whichever was recorded first) until the first date of disease progression or death. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.
Time frame: From first date recorded for CR or PR until the first date of disease progression or death (last participant with tumor response progressed 6.5 months after documented response).
Median Time to Response
Time to response was defined as the number of weeks from first dose of study therapy (ixabepilone or cetuximab) until measurement criteria were first met for PR or CR, whichever status was recorded first. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.
Time frame: Time from first dose of study therapy until first date of PR or CR. Maximum time to response was 19 months.
Number of Participants With Death Within 30 Days of Last Dose, Any Serious Adverse Event (SAE), Any Adverse Event (AE) Leading to Discontinuation (DC), or Any Treatment-related AEs By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr)
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization/causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, or is an important medical event.
Time frame: From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.
Number of Participants With Most Common Treatment-related Nonhematologic AE (>25%) By CTC v3 Grade (Gr)
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. Acneform rash and peripheral neuropathy were captured by multiple MedDRA preferred terms. Acneform rash included rash, rash pustular, and rash pruritic preferred terms. Peripheral neuropathy included neuromuscular toxicity, peripheral motor neuropathy, and peripheral sensorimotor neuropathy preferred terms.
Time frame: From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.
Number of Participants With Hematology, Liver Function, and Renal Laboratory Abnormalities By CTC v3 Grade (Gr)
Laboratory results were graded according to CTC v 3.0. Hematology laboratory evaluations included absolute neutrophil count (ANC), white blood cell count (WBC), platelets (PLT), and hemoglobin (HGB). Liver function laboratory evaluations included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin. Renal function laboratory evaluation included creatinine.
Time frame: From the time of first dose of study drug to ≤30 days after the end of the last dose of study drug or until resolution of study drug-related toxicity.
Number of Participants With Dose Reduction, Dose Delay, or Dose Interruption
Dose reduction of ixabepilone and/or cetuximab due to toxicity was permitted for participants deriving benefit from therapy. Each drug could be dose modified independently of the others. Participants unable to start a cycle due to unacceptable toxicity related to ixabepilone or cetuximab could have therapy delayed for up to 4 weeks. If toxicities prevented the administration of ixabepilone or cetuximab therapy, participants continued receiving the other therapy as scheduled. A dose interruption for ixabepilone or cetuximab was defined as any interruption during the infusion period.
Time frame: From the first dosing date of Cycle 1 until the last dosing date of the last cycle. Last dosing cycle for a participant was Cycle 21.
Percentage of Participants With Baseline Epidermal Growth Factor Receptor (EGFR) Tumor Expression
EGFR expression was evaluated by means of an immunohistochemical assay using tumor tissue collected prior to receiving first dose.
Time frame: Baseline
Change From Baseline in FHSI-8 Total Score by Time-point
The FHSI-8 includes eight items representing pancreatic-related symptoms; each symptom is rated by participants on a scale of from 0 to 4. The FHSI-8 total score ranges in value from 0 to 32, with higher scores representing fewer symptoms and lower scores representing more symptoms. Scoring of the FHSI-8 was to be conducted according to the Functional Assessment of Chronic Illness Therapy (FACIT) manual. The symptom assessment was to include treated participants who had baseline measurement and at least one on-study measurement of FHSI-8 questionnaire.
Time frame: Baseline, Week 3, Week 6, Week 9, Week 12, Week 12, Week 18, Week 24 and every 3 weeks through end of study (participant death/withdrawal from study)
| Milestone | Ixabepilone + Cetuximab |
|---|---|
| Started | 54 |
| Completed | 0 |
| Not completed | 54 |
| Withdrew: Adverse event not related to study drug | 3 |
| Withdrew: Death | 2 |
| Withdrew: Disease progression | 38 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Other | 1 |
| Withdrew: Study drug toxicity | 4 |
| Withdrew: Request to discontinue treatment | 4 |
| Withdrew: Participant withdrew consent | 1 |
The percentage of participants surviving at 6 months was defined as the number of treated participants who had not died prior to 6 months from the date of their first dose divided by the total number of treated participants.
| percentage of participants | Ixabepilone + Cetuximab |
|---|---|
| Percentage of Participants Surviving at 6 Months | 57.4 (43.2 to 70.8) |
Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD; Stable Disease (SD)= neither PR nor progressive disease (PD) criteria were met; PD = at least 20% increase in the sum of the LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.
| participants | Ixabepilone + Cetuximab |
|---|---|
| Participants with Complete Response | 0 |
| Participants with Partial Response | 4 |
| Participants with Stable Disease | 24 |
| Participants with Progressive Disease | 2 |
| Participants with Response Unable to be Determined | 1 |
Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. Tumor response was assessed according RECIST criteria: PR=at least 30% reduction in the sum of the LD of all target lesions in reference to the baseline sum LD, CR=Disappearance of all non-target lesions.
| percentage of participants | Ixabepilone + Cetuximab |
|---|---|
| Percentage of Participants With Objective Tumor Response | 12.9 (3.6 to 29.8) |
Progression-Free Survival (PFS) time was defined as the time, in months, from the first dosing date until the date of disease progression or death from any cause.
| months | Ixabepilone + Cetuximab |
|---|---|
| Median Progression Free Survival Time | 3.9 (2.6 to 4.4) |
Overall survival time was defined as the time in months from the first dosing date to the date of death.
| months | Ixabepilone + Cetuximab |
|---|---|
| Median Overall Survival Time | 7.6 (5.5 to 12.2) |
Duration of response was defined as the number of months from when measurement criteria were first met for CR or PR (whichever was recorded first) until the first date of disease progression or death. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.
| months | Ixabepilone + Cetuximab |
|---|---|
| Median Duration of Response | 5.7 (2.8 to 6.3) |
Time to response was defined as the number of weeks from first dose of study therapy (ixabepilone or cetuximab) until measurement criteria were first met for PR or CR, whichever status was recorded first. Complete Response (CR)= disappearance of all non-target lesions, Partial Response (PR)= at least 30% reduction in the sum of the longest diameter (LD) of all target lesions in reference to the baseline sum LD.
| weeks | Ixabepilone + Cetuximab |
|---|---|
| Median Time to Response | 8.8 (5.1 to 19.0) |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization/causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, or is an important medical event.
| participants | Ixabepilone + Cetuximab |
|---|---|
| All deaths within 30 days of last dose | 7 |
| Any SAE | 32 |
| Gr 2 (moderate) AE leading to DC | 2 |
| Gr 3 (severe) AE leading to DC | 9 |
| Gr 4 (life-threatening) AE leading to DC | 3 |
| All AEs leading to DC | 14 |
| Gr 1 (mild) treatment-related AE | 4 |
| Gr 2 (moderate) treatment-related AE | 13 |
| Gr 3 (severe) treatment-related AE | 25 |
| Gr 4 (life-threatening) treatment-related AE | 10 |
| Gr 5 (death) treatment-related AE | 1 |
| All treatment-related AEs | 53 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition not necessarily having a causal relationship with this treatment. Acneform rash and peripheral neuropathy were captured by multiple MedDRA preferred terms. Acneform rash included rash, rash pustular, and rash pruritic preferred terms. Peripheral neuropathy included neuromuscular toxicity, peripheral motor neuropathy, and peripheral sensorimotor neuropathy preferred terms.
| participants | Ixabepilone + Cetuximab |
|---|---|
| Gr 1 (mild) acneform rash | 21 |
| Gr 2 (moderate) acneform rash | 13 |
| Gr 3 (severe) acneform rash | 1 |
| All acneform rash | 35 |
| Gr 1 (mild) fatigue | 8 |
| Gr 2 (moderate) fatigue | 13 |
| Gr 3 (severe) fatigue | 8 |
| Gr 4 (life-threatening) fatigue | 1 |
| All fatigue | 30 |
| Gr 1 (mild) alopecia | 13 |
| Gr 2 (moderate) alopecia | 12 |
| All alopecia | 25 |
| Gr 1 (mild) nausea | 13 |
| Gr 2 (moderate) nausea | 6 |
| Gr 3 (severe) nausea | 3 |
| All nausea | 22 |
| Gr 1 (mild) diarrhea | 11 |
| Gr 2 (moderate) diarrhea | 4 |
| Gr 3 (severe) diarrhea | 1 |
| Gr 4 (life-threatening) diarrhea | 2 |
| All diarrhea | 18 |
| Gr 1 (mild) vomiting | 12 |
| Gr 2 (moderate) vomiting | 2 |
| Gr 3 (severe) vomiting | 3 |
| All vomiting | 17 |
| Gr 1 (mild) peripheral neuropathy | 12 |
| Gr 2 (moderate) peripheral neuropathy | 1 |
| Gr 3 (severe) peripheral neuropathy | 3 |
| All peripheral neuropathy | 16 |
| Gr 1 (mild) hypomagnesemia | 7 |
| Gr 2 (moderate) hypomagnesemia | 4 |
| Gr 3 (severe) hypomagnesemia | 1 |
| Gr 4 (life-threatening) hypomagnesemia | 3 |
| All hypomagnesemia | 15 |
Laboratory results were graded according to CTC v 3.0. Hematology laboratory evaluations included absolute neutrophil count (ANC), white blood cell count (WBC), platelets (PLT), and hemoglobin (HGB). Liver function laboratory evaluations included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin. Renal function laboratory evaluation included creatinine.
| participants | Ixabepilone + Cetuximab |
|---|---|
| Gr 0 (no abnormality) WBC, n=51 | 12 |
| Gr 1 (mild) WBC, n=51 | 9 |
| Gr 2 (moderate) WBC, n=51 | 9 |
| Gr 3 (severe) WBC, n=51 | 17 |
| Gr 4 (life-threatening) WBC, n=51 | 4 |
| Gr 1-4 WBC, n=51 | 39 |
| Gr 3-4 WBC, n=51 | 21 |
| Gr 0 (no abnormality) ANC, n=50 | 12 |
| Gr 1 (mild) ANC, n=50 | 8 |
| Gr 2 (moderate) ANC, n=50 | 12 |
| Gr 3 (severe) ANC, n=50 | 10 |
| Gr 4 (life-threatening) ANC, n=50 | 8 |
| Gr 1-4 ANC, n=50 | 38 |
| Gr 3-4 ANC, n=51 | 18 |
| Gr 0 (no abnormality) platelet count, n=51 | 29 |
| Gr 1 (mild) platelet count, n=51 | 18 |
| Gr 2 (moderate) platelet count, n=51 | 4 |
| Gr 1-4 platelet count, n=51 | 2 |
| Gr 0 (no abnormality) HGB, n=51 | 3 |
| Gr 1 (mild) HGB, n=51 | 28 |
| Gr 2 (moderate) HGB, n=51 | 18 |
| Gr 3 (severe) HGB, n=51 | 2 |
| Gr 1-4 HGB, n=51 | 48 |
| Gr 3-4 HGB, n=51 | 2 |
| Gr 0 (no abnormality) ALT, n=46 | 31 |
| Gr 1 (mild) ALT, n=46 | 10 |
| Gr 2 (moderate) ALT, n=46 | 3 |
| Gr 3 (severe) ALT, n=46 | 2 |
| Gr 1-4 ALT, n=46 | 15 |
| Gr 3-4 ALT, n=46 | 2 |
| Gr 0 (no abnormality) AST, n=47 | 28 |
| Gr 1 (mild) AST, n=47 | 17 |
| Gr 3 (severe) AST, n=47 | 2 |
| Gr 1-4 AST, n=47 | 19 |
| Gr 3-4 AST, n=47 | 2 |
| Gr 0 (no abnormality) alkaline phosphatase, n=47 | 18 |
| Gr 1 (mild) alkaline phosphatase, n=47 | 20 |
| Gr 2 (moderate) alkaline phosphatase, n=47 | 5 |
| Gr 3 (severe) alkaline phosphatase, n=47 | 4 |
| Gr 1-4 alkaline phosphatase, n=47 | 29 |
| Gr 3-4 alkaline phosphatase, n=47 | 4 |
| Gr 0 (no abnormality) total bilirubin, n=48 | 42 |
| Gr 1 (mild) total bilirubin, n=48 | 1 |
| Gr 2 (moderate) total bilirubin, n=48 | 1 |
| Gr 3 (severe) total bilirubin, n=48 | 4 |
| Gr 1-4 total bilirubin, n=48 | 6 |
| Gr 3-4 total bilirubin, n=48 | 4 |
| Gr 0 (no abnormality) creatinine, n=48 | 45 |
| Gr 1 (mild) creatinine, n=48 | 3 |
| Gr 1-4 creatinine, n=48 | 3 |
Dose reduction of ixabepilone and/or cetuximab due to toxicity was permitted for participants deriving benefit from therapy. Each drug could be dose modified independently of the others. Participants unable to start a cycle due to unacceptable toxicity related to ixabepilone or cetuximab could have therapy delayed for up to 4 weeks. If toxicities prevented the administration of ixabepilone or cetuximab therapy, participants continued receiving the other therapy as scheduled. A dose interruption for ixabepilone or cetuximab was defined as any interruption during the infusion period.
No measurements were reported for this outcome.
EGFR expression was evaluated by means of an immunohistochemical assay using tumor tissue collected prior to receiving first dose.
No measurements were reported for this outcome.
The FHSI-8 includes eight items representing pancreatic-related symptoms; each symptom is rated by participants on a scale of from 0 to 4. The FHSI-8 total score ranges in value from 0 to 32, with higher scores representing fewer symptoms and lower scores representing more symptoms. Scoring of the FHSI-8 was to be conducted according to the Functional Assessment of Chronic Illness Therapy (FACIT) manual. The symptom assessment was to include treated participants who had baseline measurement and at least one on-study measurement of FHSI-8 questionnaire.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixabepilone + Cetuximab | — | 32/54 (59.3%) | 49/54 (90.7%) |
| Event | Ixabepilone + Cetuximab |
|---|---|
| HYPOTENSIONVascular disorders | 6/54 |
| PANCREATIC CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/54 |
| DEHYDRATIONMetabolism and nutrition disorders | 5/54 |
| VOMITINGGastrointestinal disorders | 4/54 |
| HYPERSENSITIVITYImmune system disorders | 3/54 |
| NAUSEAGastrointestinal disorders | 3/54 |
| PYREXIAGeneral disorders | 3/54 |
| ATRIAL FIBRILLATIONCardiac disorders | 2/54 |
| DEEP VEIN THROMBOSISVascular disorders | 2/54 |
| DIARRHOEAGastrointestinal disorders | 2/54 |
| Event | Ixabepilone + Cetuximab |
|---|---|
| FATIGUEGeneral disorders | 34/54 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 29/54 |
| NAUSEAGastrointestinal disorders | 25/54 |
| ALOPECIASkin and subcutaneous tissue disorders | 25/54 |
| DIARRHOEAGastrointestinal disorders | 22/54 |
| CONSTIPATIONGastrointestinal disorders | 20/54 |
| VOMITINGGastrointestinal disorders | 18/54 |
| ABDOMINAL PAINGastrointestinal disorders | 17/54 |
| ANOREXIAMetabolism and nutrition disorders | 17/54 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 17/54 |
| Age, Continuous(years) | Ixabepilone + Cetuximab |
|---|---|
| Median | 63.0 (47.0 to 84.0) |
| Age, Customized(participants) | Ixabepilone + Cetuximab |
|---|---|
| Age Greater than, equal to 65 years | 22 |
| Age less than 65 years | 32 |
| Sex: Female, Male(Participants) | Ixabepilone + Cetuximab |
|---|---|
| Female | 19 |
| Male | 35 |
The record gives a start of Jan 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixabepilone · Cetuximab